World Healthcare Report
SEE OTHER BRANDS

Keeping up with healthcare and wellness news from the world

World Healthcare Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.

Press releases published on April 30, 2025

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for …

Altimmune to Participate in the Citizens Life Sciences Conference

Altimmune to Participate in the Citizens Life Sciences Conference

GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life …

Quipt Home Medical Corp. to Announce Fiscal Second Quarter 2025 Financial Results on May 12, 2025

Quipt Home Medical Corp. to Announce Fiscal Second Quarter 2025 Financial Results on May 12, 2025

CINCINNATI, April 30, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal Second quarter 2025 financial …

Apertura Gene Therapy and Rett Syndrome Research Trust Collaborate to Pioneer Advanced Genetic Medicines for Rett Syndrome Using TfR1-Targeted AAV Capsid

Apertura Gene Therapy and Rett Syndrome Research Trust Collaborate to Pioneer Advanced Genetic Medicines for Rett Syndrome Using TfR1-Targeted AAV Capsid

NEW YORK and TRUMBULL, Conn., April 30, 2025 (GLOBE NEWSWIRE) -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, and the Rett Syndrome Research Trust (RSRT), an organization working to cure Rett Syndrome, today …

InflaRx to Report First Quarter 2025 Results on May 7, 2025

InflaRx to Report First Quarter 2025 Results on May 7, 2025

JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial …

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Citizens Life Sciences Conference in New York on Thursday, May 8, …

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim …

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Sanofi and CD…

Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public

Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public

Sanofi et CD…

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today …

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer …

Veri Medtech (VRHI) Relaunches Veriheal.com

Veri Medtech (VRHI) Relaunches Veriheal.com

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Veri Medtech (Stock Ticker Symbol: “VRHI”) announced today that it has relaunched its Veriheal.com healthcare technology platform. For more information, please visit: www.Veriheal.com. “Veri Medtech (VRHI) has …

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that …

10 Barrel Brewing Launches Non-Alcoholic Apocalypse IPA, a Bold Craft Brew for Your Next Adventure

10 Barrel Brewing Launches Non-Alcoholic Apocalypse IPA, a Bold Craft Brew for Your Next Adventure

BEND, Ore., April 30, 2025 (GLOBE NEWSWIRE) -- 10 Barrel Brewing, a Tilray Brands, Inc., (NASDAQ: TLRY and TSX: TLRY) craft beer brand, is excited to announce the launch of NA Apocalypse IPA, a non-alcoholic version of their beloved Apocalypse IPA. This …

Nusano Names Rachel Culbertson VP of Supply Chain

Nusano Names Rachel Culbertson VP of Supply Chain

WEST VALLEY CITY, Utah, April 30, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the appointment of Rachel Culbertson as Vice President of Supply Chain. Culbertson’s leadership will be …

ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing …

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Larimar Therapeutics Reports First Quarter 2025 Financial Results

FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end …

Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement

Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement

Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreement Investments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long- …

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service